Compare InMode Ltd. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 893 Million (Small Cap)
7.00
NA
0.00%
-0.81
22.89%
1.37
Revenue and Profits:
Net Sales:
96 Million
(Quarterly Results - Jun 2025)
Net Profit:
27 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.43%
0%
4.43%
6 Months
7.87%
0%
7.87%
1 Year
-17.37%
0%
-17.37%
2 Years
-39.22%
0%
-39.22%
3 Years
-58.64%
0%
-58.64%
4 Years
-68.69%
0%
-68.69%
5 Years
-55.5%
0%
-55.5%
InMode Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
20.48%
EBIT Growth (5y)
18.98%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.83
Sales to Capital Employed (avg)
0.61
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
79.98%
ROCE (avg)
3,019.95%
ROE (avg)
30.67%
Valuation key factors
Factor
Value
P/E Ratio
7
Industry P/E
Price to Book Value
2.00
EV to EBIT
6.61
EV to EBITDA
6.56
EV to Capital Employed
6.83
EV to Sales
1.85
PEG Ratio
0.40
Dividend Yield
NA
ROCE (Latest)
103.34%
ROE (Latest)
28.38%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Bullish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 77 Schemes (14.14%)
Foreign Institutions
Held by 129 Foreign Institutions (22.08%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
95.60
86.40
10.65%
Operating Profit (PBDIT) excl Other Income
23.10
18.50
24.86%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
26.70
23.80
12.18%
Operating Profit Margin (Excl OI)
239.30%
211.80%
2.75%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 10.65% vs -36.52% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 12.18% vs -57.27% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
394.80
492.00
-19.76%
Operating Profit (PBDIT) excl Other Income
113.30
196.30
-42.28%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
181.30
197.90
-8.39%
Operating Profit Margin (Excl OI)
285.00%
397.60%
-11.26%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -19.76% vs 8.30% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -8.39% vs 22.54% in Dec 2023
About InMode Ltd. 
InMode Ltd.
Pharmaceuticals & Biotechnology
Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company’s proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company’s products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.






